nQ in the News
November 2017: nQ Medical takes unanimous 1st place at the PRISME Forum AI Startup Contest.
Read Article: Business Insider
Everyone has a unique typing signature. Research has revealed that the way we interact with computers and mobile devices can reveal with startling accuracy the presence of certain neuro-motor diseases. This Massachusetts Institute of Technology discovered/Michael J. Fox Foundation validated artificial intelligence tool (neuroQWERTY) has opened a broad opportunity to better diagnose diseases, track disease progression, and monitor medication effectiveness and symptoms.
We’ve found rich information hidden in the way our fingers interact with smart devices, that allows for motor impairment tracking and potentially early detection of neurodegenerative disease onset.
Our algorithms detect the subtle psychomotor impairment typical of these diseases by analyzing the timing of keystrokes. No information of what you are typing is captured. No hardware changes required.
A Modern Neurological Disease Detection Platform
nQ supports diagnosis of neurodegenerative disease years earlier than current gold standard tools. (Read our clinical Studies). Physicians can now prescribe with confidence, having unparalleled access to 24/7 real-time data from patient’s personal devices. With earlier diagnosis, granular tracking of disease progression, and ongoing measurement of therapeutic impact, nQ reveals insights to help the clinician “see.”
Addressing Real Clinical Trial challenges
- Better, faster identification of ideal study participants for fewer required subjects/bigger effect size
- Less in-clinic observation (at-home, unbiased, real-world data) improves compliance/saves money
- Passive/continuous monitoring yields earlier measure of drug impact and increased speed to FDA approval/market launch
An End-to-End Machine Learning Platform for the Entire Drug Development Lifecycle
Unified data management across the entire lifecycle, from clinical trials to clinician dashboards, from patient engagement to population health allowing for a completely integrated experience. Our machine learning approach provides a whole perspective of patient data.
For Pharma/Medical Device, Clinician, and Patient
nQ collects and processes data passively, 24/7, from daily interaction with personal devices (lap top, desktop, tablet, and smartphone). We allow clinicians and patients to view and monitor their personal data and share and interact with each other accordingly.
Mr. Bavasso is one of the early pioneers of use of digital media, devices and the web as tools to support pharmaceutical sales and marketing strategies and tactics. Since 1999, he has worked with top 25 Pharma clients globally to introduce the Closed Loop Marketing (CLM) function. He has set procedure and precedent in the areas of sales force effectiveness, business-rule driven content management, multichannel marketing, and mobile technology. A frequent speaker at industry conferences and events, Mr. Bavasso serves as an advocate for the industry in promoting digital conversation as integral to the various enterprise functions within pharma and the medical community.
Prior to his seven years as co-founder and President of Exploria SPS, Mr. Bavasso served for sixteen years as CEO of Pharmedica Holdings, LLC, and President of its INFLUENT Division, at the time one of the largest medical education companies in the world. He built Pharmedica holdings from its start as a meetings planning company in 1992, doubling its revenues each year until its sale in 2001. This growth included an ACCME accredited entity (Center for Medical Education, LLC), a digital content division (Influent, LLC), and a call center (ContextMedicus, LLC). He opened offices in California, Connecticut, Illinois, and North Carolina. After his three-year earn out, Bavasso partnered to co-found Exploria SPS, LLC, as the mobile devices division of Exploria, Inc. Within three years, Exploria SPS became the market leader for CLM with offices in Connecticut and France and currently licenses software in 33 countries and 18 languages. Mr. Bavasso’s introduction of CLM and subsequent influence over the growth and expansion of CLM globally led to his recognition in 2007, by PharmaVoice magazine as one of the top 100 most influential people in pharma. Foreseeing the trends in Pharma that have impacted its selling model and the changing influence dynamic of payors on prescribing, Mr. Bavasso incubated a new and disruptive concept meant to serve as the transaction-fed, new marketplace for healthcare. This led to the incorporation of RIMEDIO, Inc. in October 2012 intent on reshaping the dynamic of how healthcare interacts and transacts to achieve mutual stakeholder objectives. RIMEDIO leverages the power of social utilities with eCommerce, content management and communications tools to consummate transactions between healthcare stakeholders. He is currently co-founder and CEO of nQ Medical, Inc., a machine learning computational biomarker company leveraging keyboard data to manage neuromotor diseases. Everyone has a unique typing signature. Research has revealed that the way we interact with computers and mobile devices can reveal with startling accuracy the presence of certain neuro-motor diseases. This Massachusetts Institute of Technology discovered/Michael J. Fox Foundation validated artificial intelligence tool (neuroQWERTY) has opened a broad opportunity to better diagnose diseases, track disease progression, and monitor medication effectiveness and symptoms. Mr. Bavasso is also a licensed hospital administrator having served from 1981 to 1992 leading two health care systems in New England. A graduate of Pepperdine University, Malibu, CA, with a Bachelor of Science degree in business administration, he received his MBA in health care management and finance from Bryant University, Smithfield, RI.
Teresa Arroyo Gallego
Lead Data Scientist
Teresa Arroyo-Gallego, PhD, is the Lead Data Scientist at nQ Medical Inc. Using machine learning to detect and monitor psychomotor impairment via passive data collection from users’ natural interaction with their personal devices, she provides an innovative solution for diagnosis and monitoring of neurodegenerative diseases. She was on the original research team that conceived and developed the technology in the MIT labs.
At nQ, Dr. Arroyo-Gallego is responsible for overseeing and designing R&D activities and studies to validate and improve the nQ technology. She is also a Visiting Scholar at the Massachusetts Institute of Technology (MIT), where she continues to work on research activities to evaluate and explore new areas of machine learning application.
Dr. Arroyo-Gallego is a computer scientist and biomedical engineer with a research focus on the application of artificial intelligence to develop innovative solutions for healthcare problems. In the early years of her scientific career, she worked in different biomedical research groups what allowed her to further develop her technical skills and provided her an excellent experience and understanding of the multidisciplinary environment in the biomedical engineering world. These experiences confirmed her passion and commitment to dedicate her career to improve people’s health.
DAVID KREUTTER, PH.D., PFIZER, KREUTTER LIFE SCIENCES LLC | DAVID LEE SCHER, MD, CARDIOLOGIST, DIGITAL HEALTH CONSULTANT | MARK PASCARELLA, MBA, INVESTOR, FOUNDERS WANTED, ZOLTAN MARI, MD, Chief, Movement Disorder Program, The Cleveland Clinic Lou Ruvo Center for Brain Health | Naomi Fried, CEO, Health Innovation Strategies
Interested in learning more about nQ Medical? Send us a message and let us know how we can help.
nQ Medical Inc. Copyright 2017 All rights reserved.